Vanila Singh - 22 Mar 2022 Form 4 Insider Report for BIODELIVERY SCIENCES INTERNATIONAL INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 22 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Mar 2022, 17:17:22 UTC
Prior SEC filing: 31 Jan 2022
Next SEC filing: 04 Jan 2023
Source filing: View source filing
Reporting owner signature: Dr. Vanila M. Singh

Key filing fact

Vanila Singh filed Form 4 for BIODELIVERY SCIENCES INTERNATIONAL INC on 22 Mar 2022.

Key facts

This page summarizes Vanila Singh's Form 4 filing for BIODELIVERY SCIENCES INTERNATIONAL INC.
5 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 22 Mar 2022, 17:17.

Change

Previous filing in this sequence was filed on 31 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BDSI transaction

Common Stock

Other

Transaction value: $0
Shares: -35,851
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 22 Mar 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BDSI transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value: $0
Shares: -17,019
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 22 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,019
Exercise price: $0.000000
Footnotes: F2, F3

BDSI transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -81,008
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 22 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 81,008
Exercise price: $4.36
Footnotes: F4

BDSI transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -48,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 22 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 48,000
Exercise price: $3.76
Footnotes: F4

BDSI transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -85,760
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 22 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 85,760
Exercise price: $3.66
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Vanila Singh is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

Footnote F2

Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

Footnote F3

Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

Footnote F4

Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.